Cognitive Function After Cardiopulmonary Bypass and Deep Hypothermic Circulatory Arrest in Management of Renal Cell Carcinoma With Vena Caval Thrombus - 22/09/22
, Xiaoying Yao 2, †, Hongyang Qian 1, †, Jin Zhang 1, Wen Kong 1, Xiaorong Wu 1, Yiran Huang 1, Yonghui Chen 1, ⁎
, Wei Xue 1, ⁎Abstract |
Objective |
To compare cognitive outcomes of patients undergoing open radical nephrectomy (RN) and inferior vena cava (IVC) thrombectomy with vs without cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest.
Patients and Methods |
A prospective, 6-month, observational study was conducted from January 2013 to December 2019 in renal cell carcinoma patients with level II-IV IVC thrombus undergoing RN. A battery of standardized neuropsychological tests was administrated to assess multi-domain cognitive function before surgery, 1 week, and 6 months after surgery: attention, executive functions, working memory, short-term and long-term delay recall, visuomotor speed, and verbal fluency.
Results |
Cognitive impairment was defined as a 20% reduction in at least 20% of the main variables. The primary outcome was the incidence of cognitive impairment at 6 months postoperatively and was analyzed with general linear mixed models. Twenty-six patients treated with CPB and 39 treated with non-CPB were analyzed. There were no significant differences in cognitive impairment between the two groups. The incidence of cognitive impairment at 1 week postoperatively was 38.5% in CPB group and 30.8% in non-CPB group (P = .52), after 6 months 11.5% and 10.3% (P = 1.00). Multivariate analysis indicated that the estimated blood loss was the only risk factor associated with cognitive impairment at 1 week postoperatively.
Conclusion |
This study showed no significant differences in postoperative cognitive function of renal cell carcinoma patients after open RN and IVC thrombectomy with and without CPB and deep hypothermic circulatory arrest. Estimated blood loss was found to be associated with cognitive impairment at 6 months postoperatively.
Le texte complet de cet article est disponible en PDF.Plan
| Funding Support: This work was supported by 21ZR1438900 from Natural Science fund of Shanghai, PYIII20-07 from the Incubating Program for Clinical Research and Innovation of Renji Hospital, PYXJS16-008 from the Incubating Program for Clinical Research and Innovation of Renji Hospital, BCF-NH-ZL-20201119-024 from Basic Oncology Research Program of Bethune Charitable Foundation. |
Vol 167
P. 144-151 - septembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
